SK5362003A3 - Detection of infectious agents using antigen mimics - Google Patents

Detection of infectious agents using antigen mimics Download PDF

Info

Publication number: SK5362003A3
Authority: SK; Slovakia
Prior art keywords: phage; collection; hcv; sera; clones
Prior art date: 2000-11-03

Application number

SK536-2003A

Other languages

English (en)

Slovak (sk)

Inventor

Franco Felici

Nicola Gargano

Olga Minenkova

Paolo Monaci

Original Assignee

Kenton S R L

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-11-03

Filing date

2000-11-03

Publication date

2003-09-11

2000-11-03 Application filed by Kenton S R L filed Critical Kenton S R L

2003-09-11 Publication of SK5362003A3 publication Critical patent/SK5362003A3/sk

Links

239000000427 antigen Substances 0.000 title claims abstract description 46
108091007433 antigens Proteins 0.000 title claims abstract description 44
102000036639 antigens Human genes 0.000 title claims abstract description 44
238000001514 detection method Methods 0.000 title claims abstract description 11
239000012678 infectious agent Substances 0.000 title description 6
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 93
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 53
210000002966 serum Anatomy 0.000 claims abstract description 51
238000000034 method Methods 0.000 claims abstract description 45
239000003446 ligand Substances 0.000 claims abstract description 36
238000012216 screening Methods 0.000 claims abstract description 18
238000003745 diagnosis Methods 0.000 claims abstract description 11
230000035800 maturation Effects 0.000 claims abstract description 4
238000000338 in vitro Methods 0.000 claims abstract description 3
230000009257 reactivity Effects 0.000 claims description 39
239000000203 mixture Substances 0.000 claims description 31
238000003556 assay Methods 0.000 claims description 17
150000001413 amino acids Chemical class 0.000 claims description 14
238000012360 testing method Methods 0.000 claims description 13
208000015181 infectious disease Diseases 0.000 claims description 11
235000001014 amino acid Nutrition 0.000 claims description 10
208000005176 Hepatitis C Diseases 0.000 claims description 7
238000002360 preparation method Methods 0.000 claims description 7
230000003248 secreting effect Effects 0.000 claims description 7
229960005486 vaccine Drugs 0.000 claims description 6
238000001261 affinity purification Methods 0.000 claims description 5
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 5
230000010076 replication Effects 0.000 claims 2
241000282320 Panthera leo Species 0.000 claims 1
241000711549 Hepacivirus C Species 0.000 description 56
238000002965 ELISA Methods 0.000 description 26
230000000903 blocking effect Effects 0.000 description 11
239000000872 buffer Substances 0.000 description 11
108090000623 proteins and genes Proteins 0.000 description 10
235000018102 proteins Nutrition 0.000 description 8
102000004169 proteins and genes Human genes 0.000 description 8
230000000890 antigenic effect Effects 0.000 description 6
238000011534 incubation Methods 0.000 description 6
239000006228 supernatant Substances 0.000 description 6
239000011534 wash buffer Substances 0.000 description 6
238000009007 Diagnostic Kit Methods 0.000 description 5
241000700605 Viruses Species 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
101710144111 Non-structural protein 3 Proteins 0.000 description 4
101710193132 Pre-hexon-linking protein VIII Proteins 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
238000002405 diagnostic procedure Methods 0.000 description 4
230000008348 humoral response Effects 0.000 description 4
239000000463 material Substances 0.000 description 4
230000008569 process Effects 0.000 description 4
239000000243 solution Substances 0.000 description 4
241000283707 Capra Species 0.000 description 3
208000035473 Communicable disease Diseases 0.000 description 3
108010067902 Peptide Library Proteins 0.000 description 3
238000003314 affinity selection Methods 0.000 description 3
238000012512 characterization method Methods 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
229920000136 polysorbate Polymers 0.000 description 3
239000013641 positive control Substances 0.000 description 3
230000035945 sensitivity Effects 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
108010032595 Antibody Binding Sites Proteins 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
238000012286 ELISA Assay Methods 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
241000724791 Filamentous phage Species 0.000 description 2
101000666856 Homo sapiens Vasoactive intestinal polypeptide receptor 1 Proteins 0.000 description 2
241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
241000713340 Human immunodeficiency virus 2 Species 0.000 description 2
239000004677 Nylon Substances 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
102000003992 Peroxidases Human genes 0.000 description 2
229920001213 Polysorbate 20 Polymers 0.000 description 2
238000012300 Sequence Analysis Methods 0.000 description 2
102100038388 Vasoactive intestinal polypeptide receptor 1 Human genes 0.000 description 2
208000036142 Viral infection Diseases 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
238000013459 approach Methods 0.000 description 2
239000005018 casein Substances 0.000 description 2
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
235000021240 caseins Nutrition 0.000 description 2
238000011161 development Methods 0.000 description 2
230000000694 effects Effects 0.000 description 2
238000006911 enzymatic reaction Methods 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
230000004927 fusion Effects 0.000 description 2
208000006454 hepatitis Diseases 0.000 description 2
238000003018 immunoassay Methods 0.000 description 2
238000003119 immunoblot Methods 0.000 description 2
208000019423 liver disease Diseases 0.000 description 2
239000012528 membrane Substances 0.000 description 2
150000007523 nucleic acids Chemical group 0.000 description 2
229920001778 nylon Polymers 0.000 description 2
239000002245 particle Substances 0.000 description 2
108040007629 peroxidase activity proteins Proteins 0.000 description 2
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
230000004044 response Effects 0.000 description 2
230000009385 viral infection Effects 0.000 description 2
238000005406 washing Methods 0.000 description 2
241000347487 Adamsia Species 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
108010077805 Bacterial Proteins Proteins 0.000 description 1
206010008909 Chronic Hepatitis Diseases 0.000 description 1
206010009208 Cirrhosis alcoholic Diseases 0.000 description 1
108091035707 Consensus sequence Proteins 0.000 description 1
241000274965 Cyrestis thyodamas Species 0.000 description 1
102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
241001414890 Delia Species 0.000 description 1
101100028477 Drosophila melanogaster Pak gene Proteins 0.000 description 1
238000008157 ELISA kit Methods 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
108700039791 Hepatitis C virus nucleocapsid Proteins 0.000 description 1
101710121996 Hexon protein p72 Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
101710125418 Major capsid protein Proteins 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
101800001019 Non-structural protein 4B Proteins 0.000 description 1
206010029719 Nonspecific reaction Diseases 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
208000037581 Persistent Infection Diseases 0.000 description 1
239000004952 Polyamide Substances 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
108020000999 Viral RNA Proteins 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
230000009824 affinity maturation Effects 0.000 description 1
208000010002 alcoholic liver cirrhosis Diseases 0.000 description 1
230000036436 anti-hiv Effects 0.000 description 1
230000001188 anti-phage Effects 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
244000309466 calf Species 0.000 description 1
210000000234 capsid Anatomy 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
238000002809 confirmatory assay Methods 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
238000013461 design Methods 0.000 description 1
239000007973 glycine-HCl buffer Substances 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000007774 longterm Effects 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
238000011169 microbiological contamination Methods 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
239000013642 negative control Substances 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
229940023041 peptide vaccine Drugs 0.000 description 1
238000002823 phage display Methods 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
229920002647 polyamide Polymers 0.000 description 1
108020001580 protein domains Proteins 0.000 description 1
231100000654 protein toxin Toxicity 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000003908 quality control method Methods 0.000 description 1
238000011002 quantification Methods 0.000 description 1
238000012340 reverse transcriptase PCR Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
238000011896 sensitive detection Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
235000011149 sulphuric acid Nutrition 0.000 description 1
238000001308 synthesis method Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Pathology (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
General Physics & Mathematics (AREA)
Microbiology (AREA)
Food Science & Technology (AREA)
Communicable Diseases (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Virology (AREA)
Peptides Or Proteins (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

SK536-2003A 2000-11-03 2000-11-03 Detection of infectious agents using antigen mimics SK5362003A3 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/IT2000/000442 WO2002037115A1 (en)	2000-11-03	2000-11-03	Detection of infectious agents using antigen mimics

Publications (1)

Publication Number	Publication Date
SK5362003A3 true SK5362003A3 (en)	2003-09-11

Family

ID=11133576

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK536-2003A SK5362003A3 (en)	2000-11-03	2000-11-03	Detection of infectious agents using antigen mimics

Country Status (12)

Country	Link
EP (1)	EP1332369A1 (pl)
JP (1)	JP2004513346A (pl)
KR (1)	KR20030084895A (pl)
CN (1)	CN1455866A (pl)
AU (1)	AU2001218836A1 (pl)
BR (1)	BR0017366A (pl)
CA (1)	CA2427602A1 (pl)
HU (1)	HUP0302103A3 (pl)
MX (1)	MXPA03003794A (pl)
PL (1)	PL364832A1 (pl)
SK (1)	SK5362003A3 (pl)
WO (1)	WO2002037115A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2108656A1 (en)	2008-03-19	2009-10-14	Beninati, Concetta	Antigenic protein fragments of streptococcus pneumoniae
WO2009158682A2 (en) *	2008-06-27	2009-12-30	Watkinson D Tobin	Compositions and methods for diagnosing and treating pathogenic disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2172305A1 (en) *	1995-03-30	1996-10-01	Muneo Aoyama	Multiple antigenic peptide comprising at least two hepatitis c virus-associated peptides
WO1999058561A1 (fr) *	1998-05-14	1999-11-18	Pasteur Merieux Serums & Vaccins	Mimotopes du virus de l'hepatite c

2000
- 2000-11-03 KR KR10-2003-7006153A patent/KR20030084895A/ko not_active Ceased
- 2000-11-03 JP JP2002539818A patent/JP2004513346A/ja active Pending
- 2000-11-03 CN CN00820000A patent/CN1455866A/zh active Pending
- 2000-11-03 EP EP00981607A patent/EP1332369A1/en not_active Withdrawn
- 2000-11-03 PL PL00364832A patent/PL364832A1/pl unknown
- 2000-11-03 CA CA002427602A patent/CA2427602A1/en not_active Abandoned
- 2000-11-03 HU HU0302103A patent/HUP0302103A3/hu unknown
- 2000-11-03 AU AU2001218836A patent/AU2001218836A1/en not_active Abandoned
- 2000-11-03 WO PCT/IT2000/000442 patent/WO2002037115A1/en not_active Ceased
- 2000-11-03 BR BR0017366-5A patent/BR0017366A/pt not_active IP Right Cessation
- 2000-11-03 SK SK536-2003A patent/SK5362003A3/sk not_active Application Discontinuation
- 2000-11-03 MX MXPA03003794A patent/MXPA03003794A/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
AU2001218836A1 (en)	2002-05-15
MXPA03003794A (es)	2004-10-15
WO2002037115A1 (en)	2002-05-10
CN1455866A (zh)	2003-11-12
PL364832A1 (pl)	2004-12-27
BR0017366A (pt)	2004-06-15
EP1332369A1 (en)	2003-08-06
KR20030084895A (ko)	2003-11-01
HUP0302103A3 (en)	2007-03-28
JP2004513346A (ja)	2004-04-30
HUP0302103A2 (hu)	2003-09-29
CA2427602A1 (en)	2002-05-10

Legal Events

Date	Code	Title	Description
2010-10-07	FC9A	Refused patent application

Publication	Publication Date	Title
KR100330278B1 (ko)	2002-08-19	간염c바이러스의타이핑방법및사용시약
JP3657515B2 (ja)	2005-06-08	ウイルスエンベロープ蛋白中のエピトープおよびこれらのエピトープに対して指向された特異的抗体：宿主組織中のｈｃｖウイルス抗原の検出のための使用
US6291197B1 (en)	2001-09-18	Binding moieties for human parvovirus B19
EP1328811B1 (en)	2005-08-31	Hcv mosaic antigen composition
Pang et al.	2024	Bioscreening specific peptide-expressing phage and its application in sensitive dual-mode immunoassay of SARS-CoV-2 spike antigen
US20030049608A1 (en)	2003-03-13	Hepatitis C antigen - antibody combination assay for the early detection of infection
JP2000514300A (ja)	2000-10-31	ヒトサイトメガロウイルス（ｃｍｖ）を検出するためのペプチド試薬
He et al.	1998	Identification of epitopes in cucumber mosaic virus using a phage-displayed random peptide library.
CN106939034B (zh)	2021-03-30	用于鉴定受试者所感染的hev基因型的方法和试剂盒
SK5362003A3 (en)	2003-09-11	Detection of infectious agents using antigen mimics
Minenkova et al.	2001	ADAM‐HCV, a new‐concept diagnostic assay for antibodies to hepatitis C virus in serum
Tafi et al.	1997	Identification of HCV core mimotopes: improved methods for the selection and use of disease-related phage-displayed peptides
CZ20031044A3 (cs)	2003-10-15	Způsob diagnostikování infekčních agens s využitím antigenových mimetik
JP3022954B2 (ja)	2000-03-21	タイプ特異的抗原を使用する血清学的タイプ分け方法
IE922548A1 (en)	1993-02-10	Non-a, non-b peptide
RU2133472C1 (ru)	1999-07-20	Способ диагностики активной стадии цитомегаловирусной инфекции человека
KR100454727B1 (ko)	2004-11-03	한탄바이러스 뉴클레오캡시드 단백질을 이용한 신증후출혈열 진단키트
JP2655205B2 (ja)	1997-09-17	非ａ非ｂ肝炎のアッセイ
EP0536838A2 (en)	1993-04-14	Non-A, non-B peptides
CA2162250C (en)	2007-07-17	Methods of typing hepatitis c virus and reagents for use therein
HK1059307A (en)	2004-06-25	Detection of infectious agents using antigen mimics
US20060166189A1 (en)	2006-07-27	Methods for detecting invasion of a cell
Bondarenko et al.	1999	Lack of correlation between sensitivity characteristics of the tests for hepatitis C virus antibodies estimated with serially diluted and natural low-reactive control specimens
SE503627C2 (sv)	1996-07-22	Peptid, diagnostiskt antigen och förfarande för hepatit C diagnos